Blood Money? Unpacking the Controversial Opioid Settlement in Pennsylvania
The proposed settlement with Oxycontin maker, Purdue Pharma, would raise money to clean up the opioid mess by selling more opioids. That would amount to blood money, in the opinion of some critics, and it's one reason two dozen states have rejected the settlement.
Ever wondered how a company responsible for an opioid epidemic can end up in bankruptcy court? This episode of Battling Opioids Podcast, hosted by JADonnelly and Paul Lazar, dives into the recent headlines surrounding Purdue Pharma's bankruptcy filing and the controversial settlement proposal. The company, known for making billions from Oxycontin, faces lawsuits from numerous state and local governments due to the devastating impact of opioids.
The proposed settlement, potentially worth billions, has been labeled by critics as 'blood money' because it would fund the cleanup by selling more opioids. Not all states are on board, with about half rejecting the deal and planning to continue litigation against the Sackler family, who owns Purdue Pharma. The discussion also highlights Pennsylvania's ongoing struggle with one of the highest opioid overdose death rates in the country.
You'll hear about Geisinger's efforts to reduce opioid prescriptions by 30% and their establishment of medication-assisted treatment centers across the state. If you're looking to understand the complexities and human stories behind these legal battles and community efforts, this episode offers a compelling listen.